• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Eric Rubin - Articles and news items

Merck logo

Merck receives complete response letter from U.S. FDA for investigational medicine ridaforolimusr

Industry news, News / 5 June 2012 / Merck

Ridaforolimus is an investigational oral mTOR inhibitor…

Merck logo

Update on FDA Advisory Committee vote on investigational medicine Ridaforolimus

Industry news, News / 20 March 2012 / Merck

“Merck remains confident in the potential of the investigational agent ridaforolimus…”

Merck logo

Merck and ARIAD announce presentation of results of Phase III SUCCEED trial

Industry news, News / 6 June 2011 / Merck

Merck and ARIAD Pharmaceuticals, Inc., announced the presentation of detailed results from the Phase III SUCCEED clinical trial…